NMN FDA Status 2026: Is It Legal? The Complete Timeline

The Short Version: What Changed and When

NMN went from legal (pre-2022) to excluded (November 2022) to legal again (September 2025). The ban lasted roughly three years and was reversed after industry lawsuits and citizen petitions forced the FDA to acknowledge that NMN was sold as a dietary supplement before any drug investigation began.

Date	What Happened	NMN Status
Pre-2022	NMN sold openly on Amazon, in retail stores, and online since at least 2017	Legal
May 2022	SyncoZymes received the first NDI (New Dietary Ingredient) notification acknowledgment for NMN	Legal (NDI filed)
Nov 2022	FDA reversed course: withdrew NMN's NDI status, excluded NMN from the dietary supplement definition, citing drug preclusion under DSHEA	Excluded
2023-2024	Industry fights back: NPA files citizen petitions and a federal lawsuit against the FDA; Amazon briefly removes some NMN listings	Gray area
Aug 2024	NPA files lawsuit in federal court seeking legal recognition of NMN as a dietary supplement	In litigation
Sep 29, 2025	FDA issues 26-page letter: reverses exclusion, confirms NMN is lawful for dietary supplements, restores previous NDI notifications	Legal again
Dec 2025	FDA sends individual letters to NMN manufacturers (including SyncoZymes) confirming their NDI notification status	Legal (NDI reinstated)
2026	NMN widely available on Amazon, Walmart, direct-to-consumer sites; customs no longer flagging NMN imports	Legal and stable

Why Did the FDA Ban NMN in the First Place?

The FDA argued that NMN could not be a dietary supplement because it had been "authorized for investigation as a new drug" before it was marketed as a supplement. This is called the "drug preclusion" clause under DSHEA, and it was meant to protect pharmaceutical companies' investment in drug development.

The backstory is important for understanding why this matters beyond NMN itself. The Dietary Supplement Health and Education Act of 1994 (DSHEA) is the law that governs dietary supplements in the United States. Under DSHEA, a substance can be sold as a dietary supplement if it was marketed as one before any drug investigation began. If the substance was first investigated as a drug and only later sold as a supplement, DSHEA's drug preclusion clause can block it from the supplement market.

In 2022, the FDA's position was that NMN had been authorized for investigation as a new drug (through an Investigational New Drug application, or IND) before it was marketed as a supplement, and therefore NMN fell under drug preclusion. The specific drug investigation in question was conducted by a company called Metro International Biotech, which was developing an NMN-based pharmaceutical for metabolic conditions.

The practical impact was immediate. The FDA sent warning letters. Amazon began removing NMN listings. The supplement industry faced the prospect of losing a product category worth hundreds of millions of dollars in annual sales.

DSHEA Explained: The Law Behind the NMN Fight

DSHEA (1994) is the law that separates supplements from drugs in the United States. Understanding it is essential because the entire NMN fight was about how one clause in this law is interpreted, and the outcome affects every dietary ingredient, not just NMN.

Before DSHEA, dietary supplements were regulated essentially as food additives, requiring premarket approval. The supplement industry argued this was too restrictive for products with long histories of safe use (vitamins, minerals, herbs). DSHEA created a new regulatory category: dietary supplements could go to market without FDA preapproval, as long as the manufacturer could show the ingredient was safe and the product did not make drug claims.

DSHEA included a provision meant to protect pharmaceutical investment: the drug preclusion clause. If a substance was first "authorized for investigation as a new drug" (via an IND filing) and was not already on the market as a supplement, the FDA could block it from being sold as a supplement. The intent was simple: stop supplement companies from free-riding on pharma's expensive clinical research.

The NMN case exposed a flaw in this design. Metro International Biotech filed an IND to investigate NMN as a prescription drug. The FDA seized on this filing. It used the IND to sweep NMN off the supplement market. But NMN had been on shelves since 2017. That was years before Metro's IND. DSHEA's "race to market" provision is clear. The supplement wins if it was there first. The FDA initially ignored this, then reversed after the NPA proved the timeline.

The broader lesson: DSHEA's drug preclusion clause is a blunt instrument. It was designed for a world where "supplement" and "drug candidate" were distinct categories. In the era of longevity science, where the same molecules (NMN, NAD+, rapamycin analogs) interest both supplement consumers and pharmaceutical researchers, the line is increasingly unclear. The NMN ruling clarified the timeline test, but it did not resolve the underlying tension.

How NMN Won: The "Race to Market" Argument

The NPA proved that NMN had been sold as a dietary supplement in the U.S. since at least 2017, before the IND (drug investigation) was filed. Since the supplement came first, the drug preclusion clause did not apply. The FDA acknowledged this evidence and reversed its position.

The resolution hinged on a question of timing. DSHEA's drug preclusion clause only applies if the drug investigation came first. If the supplement was on the market first, the ingredient gets to stay a supplement even if a pharma company later investigates it as a drug.

The Natural Products Association (NPA) gathered evidence showing NMN was marketed as a dietary supplement in the United States as early as 2017. This included product listings, sales records, and marketplace documentation. When the FDA reviewed this evidence in response to citizen petitions and the NPA's federal lawsuit, it concluded that NMN did indeed predate the drug investigation.

On September 29, 2025, the FDA issued a 26-page letter to the NPA and the Alliance for Natural Health (ANH), reversing its position. The FDA confirmed that NMN "is not excluded from the definition of a dietary supplement" and reinstated previously filed NDI notifications from companies like SyncoZymes. In December 2025, individual letters went out to NMN manufacturers confirming their reinstated status.

What "Legal" Actually Means for NMN in 2026

"Legal" means NMN can be sold as a dietary supplement under DSHEA. It does not mean NMN is FDA approved, FDA tested, or guaranteed safe. No dietary supplement is FDA approved the way drugs are. NMN's legal status gives it the same regulatory standing as vitamin C, fish oil, or any other supplement you can buy at a store.

This distinction is worth understanding because "FDA approved" is one of the most misunderstood phrases in health. The FDA does not approve dietary supplements before they hit the market. What it does is set rules for how they can be manufactured, labeled, and marketed. A legal dietary supplement must be produced in cGMP-compliant facilities, must not make disease claims, and must be safe when used as directed. The burden of proving safety falls on the manufacturer, not on the FDA.

For NMN specifically, "legal" in 2026 means:

• Companies can sell NMN supplements in the U.S. without legal risk from the drug preclusion clause
• Companies must file a New Dietary Ingredient Notification (NDIN) with the FDA if their NMN is from a supplier that has not already filed one
• NMN cannot be marketed with disease claims (it cannot say "treats diabetes" or "cures aging")
• NMN manufacturers must follow cGMP (current good manufacturing practices) and properly label their products
• The FDA can still take enforcement action against NMN products that are mislabeled, adulterated, or make illegal health claims

For consumers, the practical takeaway is: NMN is as legal as any other supplement on the shelf. Its legal standing does not tell you whether it works, whether the dose is right, or whether the brand you are buying is reputable. Those questions are answered by clinical evidence and third-party testing, not by regulatory status. For the evidence, see our what is NMN guide and best NMN supplements comparison.

Does the FDA Ban Mean NMN Was Unsafe?

No. The FDA never claimed NMN was unsafe. The exclusion was a legal technicality about whether a supplement or a drug investigation came first, not a safety ruling. NMN's safety profile in clinical trials remained consistent throughout the ban period.

This is a common misunderstanding that still circulates in forums and social media: the idea that the FDA "banned NMN because it's dangerous." The FDA's 2022 action was about market classification under DSHEA, not about safety. No adverse event report, no toxicology finding, and no clinical trial result triggered the exclusion.

In fact, during the three years NMN was technically excluded as a supplement, research continued to demonstrate its safety in human trials:

• Irie et al. (2020) confirmed safety of single oral doses up to 500 mg in healthy men (PubMed)
• Yoshino et al. (2021) found no serious adverse events at 250 mg/day for 10 weeks in prediabetic women, published in Science (PubMed)
• Igarashi et al. (2022) showed no safety signals at 250 mg/day for 12 weeks in older men (PubMed)
• Yi et al. (2023) tested 300, 600, and 900 mg/day for 60 days with no serious adverse events at any dose (PubMed)
• Pencina et al. (2023) found NMN well tolerated in overweight and obese middle-aged adults (PubMed)
• Morifuji et al. (2024) confirmed safety over a full 12 months of daily NMN supplementation in older adults (PubMed)

Six independent clinical trials, spanning 2020 to 2024, tested NMN at doses from 250 to 900 mg/day for durations up to 12 months. Zero serious adverse events were reported across all of them. The FDA's exclusion and its reversal were about legal classification, not safety data. For the full safety profile, see our NMN side effects guide.

The Amazon Delisting: What Actually Happened

Following the FDA's November 2022 exclusion, Amazon began removing NMN supplement listings from its marketplace. This was not an Amazon policy decision. It was Amazon's standard response to FDA regulatory actions: when the FDA says a substance is not a dietary supplement, Amazon pulls it. When the FDA reversed, Amazon restored the listings.

The Amazon removal created more confusion than the FDA letter itself. Most buyers never saw an FDA notice. They just watched their usual products vanish overnight. Social media and supplement forums filled with speculation about NMN being "dangerous" or "recalled," neither of which was true.

During the ban period, NMN remained available from direct-to-consumer websites, smaller retailers, and international sources. Brands like ProHealth, Wonderfeel, and others continued selling through their own stores, arguing that the FDA's interpretation was incorrect and would be overturned. They were right. It just took three years.

The Amazon episode illustrates a practical point: if you rely on Amazon as your sole supplement source, you are exposed to marketplace policy decisions that reflect regulatory status, not product safety. Buying directly from reputable brands with their own websites provides continuity if marketplace listings are disrupted.

NMN's Global Regulatory Status in 2026

NMN is legal as a dietary supplement in the U.S. (confirmed September 2025), legal in China (approved as a Novel Food ingredient), and NOT yet approved as a food supplement in the EU (no Novel Food authorization). The regulatory picture varies significantly by country.

Region	Status in 2026	Key Detail
United States	Legal (dietary supplement)	FDA reversed exclusion Sep 2025; NDIN required
China	Legal (Novel Food ingredient)	Approved for food use; large domestic manufacturing base
Japan	Legal (food ingredient)	Sold widely; multiple clinical trials conducted in Japan
European Union	Not authorized	No Novel Food application approved; import/sale restricted
Australia	Gray area	Not explicitly listed; TGA has not taken formal action
Canada	Not authorized as NHP	No Natural Health Product number issued for NMN

If you are ordering NMN from outside the U.S., be aware that import regulations vary by country. In the EU, NMN supplements are technically not legal to sell without Novel Food authorization, though enforcement is inconsistent. In China and Japan, NMN is widely available and has a stronger regulatory foundation than in most Western countries.

What This Means for NMN Buyers in 2026

The FDA's reversal is good news for availability but changes nothing about quality. NMN is legal to buy, but the supplement industry's quality problem predates and outlives any FDA ruling. Third-party testing, purity verification, and brand reputation remain the consumer's primary safeguards.

The irony of the FDA reversal is that NMN's regulatory status is now clearer than most supplements, because it went through a public legal fight that produced a 26-page FDA letter explicitly confirming its lawful status. Most supplements have no such explicit confirmation. They are simply sold until someone challenges them.

But legal does not mean quality-controlled. Independent analyses have found NMN products on the market that contain less NMN than labeled, that use different forms of nicotinamide compounds (not NMN), or that have degraded due to poor storage. The FDA's reversal did not add any new quality requirements beyond what DSHEA already mandates. The quality burden still falls on the consumer.

What to look for when buying NMN in 2026:

• Third-party COA (Certificate of Analysis): Any reputable NMN brand publishes COAs from independent labs confirming purity above 98%, absence of heavy metals, and accurate potency.
• NDI notification filed: The brand's NMN supplier should have a filed and acknowledged NDIN with the FDA. Ask the brand directly if you cannot find this information.
• Proper storage: NMN degrades with heat and moisture. Look for sealed, opaque packaging with desiccant. Refrigeration extends shelf life.
• Dose clarity: Avoid "proprietary blends" that hide the NMN dose behind a total blend weight. You should know exactly how many milligrams of NMN are in each serving.

For our full evaluation of NMN brands on these criteria, see the best NMN supplements (2026) guide.

How to Verify Your NMN Brand Is Compliant in 2026

With NMN's legal status restored, the market is flooded with new entrants. Not all of them are compliant. Here is how to check whether the NMN brand you are considering has done its regulatory homework.

Step 1: Check for a filed NDI notification. NMN is classified as a New Dietary Ingredient, meaning the manufacturer's supplier must have submitted a New Dietary Ingredient Notification (NDIN) to the FDA. You can search the FDA's NDI notification database at fda.gov. If the brand's supplier does not appear, the product may not be fully compliant.

Step 2: Ask for the Certificate of Analysis. A COA from an independent, ISO-accredited lab should confirm NMN purity (>98%), absence of heavy metals (lead, arsenic, mercury, cadmium), microbial counts within limits, and correct identity (it is actually NMN, not nicotinamide or NR). If the brand cannot provide a COA upon request, that is a disqualifying red flag.

Step 3: Verify the manufacturing facility. NMN supplements should be manufactured in a cGMP-registered facility. This is a DSHEA requirement. Reputable brands list their manufacturing certifications on their websites or product labels.

Step 4: Check the label for drug claims. Any NMN product that claims to "treat," "cure," "prevent," or "diagnose" a disease is violating FDA labeling rules, regardless of NMN's legal status. Structure/function claims ("supports NAD+ levels," "promotes cellular health") are legal. Disease claims are not. A product making disease claims is more likely to cut corners elsewhere.

Step 5: Evaluate the source country. Most NMN raw material is manufactured in China, which is not inherently a quality concern (China is the world's largest NMN producer with significant manufacturing expertise). What matters is whether the finished product is tested independently after import. A COA from the raw material supplier alone is insufficient. You want a COA from the finished product, tested by a U.S.-based or internationally accredited lab.

Why This Case Matters Beyond NMN

The NMN case set a precedent for how the FDA applies the drug preclusion clause under DSHEA. It established that if an ingredient was sold as a supplement before a drug investigation began, the supplement market wins. This precedent could protect other ingredients facing similar challenges in the future.

The NMN fight was not just about one molecule. It tested the boundary between the supplement industry and the pharmaceutical industry in a way that had not been tested this publicly before. The drug preclusion clause is a powerful tool: if enforced aggressively, it could allow any pharmaceutical company to "claim" a natural substance by filing an IND, then use the drug preclusion clause to sweep it off the supplement market.

The NPA's victory established that timing matters. If the supplement predates the drug investigation, the ingredient stays. This gives the supplement industry a defensible position against future attempts to use drug preclusion to remove popular ingredients from the market. NAD+ precursors, mushroom compounds, and other longevity-oriented ingredients could all face similar challenges as pharmaceutical interest in these areas grows (Pandolfi et al., 2026).

For consumers, the practical takeaway is that the system worked, slowly. The NMN ban lasted nearly three years, during which a legal product was pulled from shelves and consumers were confused about its legality. The reversal confirmed what the industry argued all along: NMN was a legitimate supplement that should never have been excluded. But the process exposed how fragile supplement access can be when regulatory interpretation shifts.

Could NMN Be Banned Again?

Unlikely, but not impossible. The FDA's September 2025 letter is a strong legal precedent, and the NPA has demonstrated its willingness to litigate. However, NMN could face new regulatory challenges if a drug company obtains FDA approval for an NMN-based pharmaceutical, or if Congress amends DSHEA.

The most realistic threat is not another FDA reversal, but a narrower challenge. Metro International Biotech (which funded much of the original NMN drug research) still holds patents on certain NMN formulations and manufacturing processes. A patent enforcement action could restrict specific NMN products or manufacturing methods without challenging NMN's supplement status broadly. This is a commercial risk, not a regulatory one, but it could affect availability and pricing for some brands.

A broader legislative change to DSHEA is also theoretically possible. Some FDA officials and pharmaceutical lobbyists have argued that the drug preclusion clause should be strengthened to better protect drug development investment. Any such amendment would face significant opposition from the supplement industry and consumer groups, but it is worth watching.

For practical purposes in 2026: NMN is stable, available, and its legal standing is as clear as any dietary supplement on the market. If you are considering NMN, regulatory risk is not a reason to hesitate.

The Clinical Evidence That Survived the Ban

Eight independent human trials, published between 2020 and 2024, demonstrated that NMN raises blood NAD+ levels, improves physical performance, enhances insulin sensitivity, and maintains functional capacity in older adults. All of this research was conducted and published regardless of NMN's regulatory status.

Science does not care about regulatory classification. The clinical evidence for NMN continued to grow throughout the ban period, in labs across Japan, China, and the United States. Here is what the published human trials show:

Study	Dose	Duration	Key Finding
Irie 2020	Up to 500 mg	Single dose	Safe in humans, raised NMN metabolites
Yoshino 2021 (Science)	250 mg/day	10 weeks	Improved muscle insulin sensitivity
Liao 2021	Variable	6 weeks	Enhanced aerobic capacity in runners
Igarashi 2022	250 mg/day	12 weeks	Elevated blood NAD+ in older men
Yi 2023	300/600/900 mg	60 days	Dose-response NAD+ increase, 600 mg optimal
Pencina 2023	MIB-626	14 days	NAD+ elevation in overweight adults
Morifuji 2024	250 mg/day	12 months	Maintained walking speed, improved sleep

This body of evidence is what separates NMN from most supplements. A 2026 review in Molecular Biology Reports noted that NMN is now one of the most clinically studied NAD+ precursors, with a growing evidence base supporting its safety and bioavailability in humans (Pandolfi et al., 2026). The NMN transporter Slc12a8, identified in the gut lining by Grozio et al. (2019), provided the mechanistic basis for why oral NMN supplementation raises blood NAD+ levels reliably (PubMed).

For the full dosage guide, see NMN dosage. For which NMN format to buy, see NMN powder vs capsules vs sublingual. For specific brand reviews, see our Wonderfeel Youngr review and ProHealth NMN review.

Frequently Asked Questions

Is NMN legal in the US in 2026?

Yes. The FDA confirmed on September 29, 2025, that NMN is lawful for use in dietary supplements. The three-year exclusion (November 2022 to September 2025) has been reversed. NMN is now sold legally on Amazon, Walmart, and direct-to-consumer websites.

Did the FDA ban NMN?

The FDA excluded NMN from the dietary supplement definition in November 2022 under the drug preclusion clause of DSHEA. This was not a safety ban. The FDA reversed this exclusion in September 2025 after the NPA provided evidence that NMN was marketed as a supplement before any drug investigation began.

Is NMN FDA approved?

No dietary supplement is "FDA approved" in the way drugs are. NMN is FDA-recognized as lawful for dietary supplement use, which means it can be legally manufactured, sold, and marketed under DSHEA rules. This is the same regulatory standing as vitamin C, fish oil, or any other supplement.

Why was NMN banned?

The FDA argued that NMN was first investigated as a drug (via an IND application by Metro International Biotech) before it was sold as a supplement, triggering the drug preclusion clause of DSHEA. The NPA proved this timeline was wrong: NMN was sold as a supplement as early as 2017, before the drug investigation. The FDA accepted this evidence and reversed the exclusion.

Is NMN safe?

Based on published human clinical trials (six studies, doses up to 900 mg/day, durations up to 12 months), NMN has demonstrated no serious adverse events. Common side effects are mild and transient: occasional GI discomfort and headache. The FDA's exclusion was not based on safety concerns.

Can I buy NMN on Amazon?

Yes. NMN supplements are widely available on Amazon as of 2026. During the 2022-2025 exclusion period, Amazon briefly removed some NMN listings, but they have been restored following the FDA's reversal. As with any supplement, verify third-party testing and brand reputation before purchasing.

Is NMN legal in Europe?

No. NMN has not received Novel Food authorization from the European Food Safety Authority (EFSA), which means it cannot be legally sold as a food supplement in the EU. Some EU-based consumers purchase NMN from U.S. or Asian sources, but this carries regulatory risk.

What is an NDI notification and does it matter?

A New Dietary Ingredient Notification (NDIN) is a premarket filing that companies must submit to the FDA before selling a "new" dietary ingredient. It provides evidence that the ingredient is reasonably expected to be safe. NMN requires an NDIN because it was not sold as a supplement before 1994 (when DSHEA was enacted). Reputable brands use suppliers with acknowledged NDIN filings.

Could NMN be banned again?

Unlikely. The FDA's September 2025 letter is a strong legal precedent, and the NPA has demonstrated its willingness to litigate. Theoretical risks include a patent enforcement action by Metro International Biotech or a future amendment to DSHEA, but neither is imminent. For practical purposes, NMN's legal status is stable.

What is the NMN 18000 supplement?

Products labeled "NMN 18000" typically contain 600 mg of NMN per capsule, with "18000" referring to the total milligrams per bottle (30 capsules x 600 mg = 18,000 mg). It is a marketing trick. The big number makes the product look higher-dose than it is. Evaluate these products by their per-capsule NMN content and third-party testing, not by the number on the bottle.

Does the FDA ruling mean NMN works?

No. The FDA ruling says NMN is legal to sell as a supplement. It makes no claims about efficacy. Whether NMN "works" is a clinical question answered by published human trials, not by regulatory status. The evidence from eight RCTs shows NMN raises NAD+ levels and produces measurable biological effects, but it has not been proven to extend lifespan or reverse aging in humans.

NMN supplement news 2026: what is the latest?

The biggest NMN news in 2025-2026 was the FDA's September 2025 reversal confirming NMN's lawful supplement status. On the research side, Morifuji et al. published the longest NMN human study to date (12 months, 2024), and Pandolfi et al. published a comprehensive NAD+ biology review in 2026. For the latest clinical evidence, see our what is NMN guide.

Is NMN legal in Canada?

NMN has not been issued a Natural Health Product (NHP) number by Health Canada, which means it cannot be legally sold as a health supplement in Canada. Canadian consumers sometimes purchase NMN from U.S.-based online retailers for personal use, but commercial sale within Canada is not authorized. This may change as more regulatory submissions are made, but as of 2026, NMN's Canadian status remains unresolved.

Is NMN legal in Australia?

The Therapeutic Goods Administration (TGA) has not formally approved or rejected NMN as a dietary supplement in Australia. NMN is not listed on the Australian Register of Therapeutic Goods. Some Australian consumers purchase NMN from international retailers, but domestic sale as a therapeutic good is not permitted without TGA listing. The regulatory environment is described as a gray area, with no formal enforcement action taken against NMN sellers but no affirmative approval either.

What is Metro International Biotech and why does it matter?

Metro International Biotech is the pharmaceutical company that filed an Investigational New Drug (IND) application to study NMN as a prescription drug, which triggered the FDA's drug preclusion argument. Metro developed an NMN formulation called MIB-626 for metabolic conditions. The company also holds patents on certain NMN manufacturing processes. While the FDA has resolved the supplement status question, Metro's patents could theoretically affect specific NMN products or manufacturing methods in the future. This is a commercial issue, not a consumer safety concern.

How does NMN compare to NR (nicotinamide riboside) in regulatory status?

NR (sold as Niagen by ChromaDex) has a smoother regulatory history. It received New Dietary Ingredient (NDI) notification acknowledgment from the FDA in 2014 and has maintained its supplement status without interruption. NR also has FDA GRAS (Generally Recognized as Safe) status for use in food and beverages. NMN's regulatory journey was rockier, but as of 2026, both are legal dietary supplement ingredients in the United States. The clinical evidence base for NMN has grown significantly in recent years and now includes more published human RCTs than NR.

Legal status tells you NMN can be sold. It does not tell you whether it works. For the evidence from 14 trials, see does NMN actually work.

Sources

• Irie J, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters. Endocr J. 2020;67(2):153-160. PubMed
• Grozio A, et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab. 2019;1(1):47-57. PubMed
• Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PubMed
• Liao B, et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners. J Int Soc Sports Nutr. 2021;18(1):54. PubMed
• Igarashi M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood NAD+ in healthy older men. NPJ Aging. 2022;8(1):5. PubMed
• Yi L, et al. The efficacy and safety of NMN supplementation in healthy middle-aged adults: a dose-dependent clinical trial. GeroScience. 2023;45(1):29-43. PubMed
• Pencina KM, et al. Nicotinamide adenine dinucleotide augmentation in overweight or obese middle-aged and older adults. J Clin Endocrinol Metab. 2023;108(8):1968-1980. PubMed
• Morifuji M, et al. Ingestion of NMN increased blood NAD levels, maintained walking speed, and improved sleep quality. GeroScience. 2024;46(5):4671-4688. PubMed
• Pandolfi S, et al. NAD+ biology and supplementation: from mechanisms to clinical perspectives. Mol Biol Rep. 2026;53(1). PubMed

Disclosure: YourHealthier sells an NMN 500mg supplement. This article covers regulatory status, not product recommendations. See our Editorial Policy.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.